Atrial Flutter
📧 Sign up to get email alerts when something new happens for Atrial Flutter.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-08-13FDA Approved: LANOXIN — Supplemental Application (Advanz Pharma (US) Corp.)
The FDA approved a supplemental application for LANOXIN (digoxin) submitted by Advanz Pharma (US) Corp.
-
CLINICAL_TRIALS trial_result · 2012-07-11Clinical Trial Update: Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes [Phase 3]
Phase 3 clinical trial update evaluating ablation of perimitral flutter after atrial fibrillation ablation and its impact on patient outcome…
-
FDA approval · 2012-06-13FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Multaq (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2012-05-08Clinical Trial Update: Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter [Phase 2, Phase 3]
This update reports the completion of a randomized, double-blind, placebo-controlled, dose-ranging study evaluating SSR149744C (50, 100, 200…
-
CLINICAL_TRIALS trial_result · 2012-05-08Clinical Trial Update: Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr [Phase 2]
A Phase 2 double-blind, placebo-controlled dose-ranging trial evaluated SSR149744c at 300 mg or 600 mg for converting atrial fibrillation or…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-02-09Clinical Trial Update: Routine Mini-invasive Electrophysiology Study for Patients Feeling Tachycardia, With a Negative Holter ECG [NA]
Completed clinical trial evaluating a routine mini-invasive electrophysiology study for patients with tachycardia and a negative Holter ECG.
-
FDA approval · 2012-01-25FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Multaq (dronedarone) filed by Sanofi-Aventis U.S. LLC. The drug is the brand Multaq with generic…
-
FDA approval · 2012-01-11FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for sotalol hydrochloride, confirming approval of a generic product. …
-
FDA approval · 2011-12-30FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Digoxin (DIGOXIN) from Hikma Pharmaceuticals USA Inc.
-
FDA label_change · 2011-12-19FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Multaq (dronedarone) submitted by Sanofi-Aventis U.S. LLC, resulting in labeling updates for…
-
FDA approval · 2011-12-12FDA Approved: NEXTERONE — Supplemental Application (Baxter Healthcare Company)
FDA approved a supplemental application for NEXTERONE (amiodarone hydrochloride) from Baxter Healthcare Company.
-
FDA approval · 2011-11-29FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for Verapamil Hydrochloride from Chartwell RX, LLC.
-
FDA approval · 2011-11-14FDA Approved: LANOXIN — Supplemental Application (Advanz Pharma (US) Corp.)
The FDA approved a supplemental application for LANOXIN (digoxin) submitted by Advanz Pharma (US) Corp., corresponding to a labeling update …
-
FDA approval · 2011-11-14FDA Approved: LANOXIN — Supplemental Application (Covis Pharma US, Inc)
FDA approved a supplemental application for LANOXIN (digoxin) from Covis Pharma US, Inc., likely resulting in labeling updates for the produ…
-
FDA approval · 2011-11-14FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals Inc)
FDA approved a supplemental application for Verapamil hydrochloride submitted by Teva Pharmaceuticals Inc. This action finalizes changes to …
-
FDA approval · 2011-10-28FDA Approved: CARTIA XT — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for CARTIA XT (diltiazem hydrochloride) under ANDA074752.
-
FDA approval · 2011-09-26FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Digoxin from Hikma Pharmaceuticals USA Inc., resulting in updated labeling for the product.
-
EMA safety_alert · 2011-09-22European Medicines Agency recommends restricting use of Multaq
The EMA recommends restricting the use of Multaq (dronedarone) due to safety concerns and safer alternatives; explicit usage restrictions an…
-
CLINICAL_TRIALS trial_result · 2011-09-22Clinical Trial Update: Cardiac Electrophysiological Study [Phase 2]
A Phase 2 clinical trial conducted by AstraZeneca evaluating a cardiac electrophysiological approach for atrial flutter has completed, with …
-
FDA approval · 2011-08-22FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2011-08-19FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (OCEANSIDE PHARMACEUTICALS)
FDA approved Oceanside Pharmaceuticals' supplemental application for diltiazem hydrochloride, allowing continued marketing of this generic p…
-
FDA approval · 2011-08-03FDA Approved: VERAPAMIL HYDROCHLORIDE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved verapamil hydrochloride as an original application generic drug by Glenmark; the product is indicated for conditions treated by…
-
FDA approval · 2011-07-11FDA Approved: PROPAFENONE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for propafenone hydrochloride, enabling its generic marketing by Strides Pharma Science Limited as a…
-
FDA approval · 2011-07-11FDA Approved: TIKOSYN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TIKOSYN (dofetilide) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2011-06-21FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC.